+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Heparin Market By Type, By Application, By Route of Administration, By End Use, By Regional Outlook, COVID-19 Impact Analysis Report and Forecast, 2021 - 2027

  • ID: 5387648
  • Report
  • June 2021
  • Region: Global
  • 239 pages
  • Marqual IT Solutions Pvt. Ltd (KBV Research)

FEATURED COMPANIES

  • B. Braun Melsungen AG
  • Fresenius SE & Co. KGaA
  • LEO Pharma A/S
  • Pfizer, Inc.
  • Sanofi S.A.
  • Viatris, Inc.
The Global Heparin Market size is expected to reach $10 billion by 2027, rising at a market growth of 6.5% CAGR during the forecast period. Heparin is also called unfractionated heparin (UFH). It refers to a glycosaminoglycan that naturally forms in the body. Heparin is widely used as an anticoagulant in medicine that acts as a blood thinner. Thus, it finds its application in the treatment of unstable angina and heart attacks. It can either injected into a vein or under the skin. Acute coronary syndrome, pulmonary embolism, atrial fibrillation, deep vein thrombosis, cardiopulmonary bypass & hemofiltration during cardiac surgery can be treated by the use of heparin. Nowadays, it is also used in major orthopedic surgeries like hip and knee replacements.

As per the data published by the Centers for Disease Control and Prevention (CDC) in 2018, it is estimated that more than 900,000 people in the U.S. are suffering from pulmonary embolism and deep vein thrombosis every year. This factor is anticipated to boost the regional demand in the forecast period. The geriatric population is at greater risk of various chronic diseases like deep vein thrombosis and pulmonary embolism. The increasing incidences of chronic diseases will positively influence the expansion of the heparin market across the globe. Moreover, the introduction of highly precise and upgraded heparin products by the market players will boost the growth of the heparin market.



COVID-19 Impact

The sudden outbreak of COVID-19 has adversely affected the healthcare sector. It has disrupted workflows in the health care system all across the globe. Due to this viral disease, a number of industries were forced to shut their doors temporarily. It also includes several subdomains of health care. However, it has a positive effect on the heparin market as there is a surge in demand for various medical services. A large number of patients who are suffering from COVID-19, their lungs are severely affected as it is a respiratory disease. The demand for heparin has been increased during the pandemic as it is used to control respiratory inflation. It causes thinning of the blood and reduces the risk of a blood clot.

Anticoagulant medications also include low molecular weight heparins which are well-tolerated and they have fewer side effects. Irrespective of risk ratings, patients who get admitted to the hospital with COVID-19 infection are treated with prophylactic-dose of low molecular weight heparin. In the suspected COVID-19 infected patients, a baseline chest CT scan is performed and they are needed to be admitted to the hospital. Various scientific studies revealed that the LMW heparin is capable of binding with SARS-CoV-2 Spike protein. So, it can be used as an effective therapeutic approach to reduce thrombosis and pulmonary embolism complications that arise in SARS-CoV-2 patients. As a result, heparin can be used in the treatment of COVID-19 patients. Though, various clinical studies & development are in progress to improve LMWH's efficacy.

Type Outlook

Based on Type, the market is segmented into Low Molecular Weight Heparin, Unfractionated Heparin and Ultra-low Molecular Weight Heparin. There is no necessity for daily blood monitoring if treated with LMWH. All these factors are expected to boost the growth of the heparin market. Furthermore, according to a scientific study that was published in NEJM Journal Watch, the low occurrence of heparin-induced thrombocytopenia is expected to contribute towards the segment growth. Ultra-low molecular weight heparin is anticipated to be the fastest-growing segment in the coming years because of the commercialization of these products with enhanced pharmacological effects.



Application Outlook

Based on Application, the market is segmented into Atrial Fibrillation, Coronary Artery Disease, Venous Thromboembolism, Renal Impairment and Other Applications. Venous thromboembolism (VTE) is expected to witness fastest growth rate in the heparin market over the forecast years. Venous thromboembolism is of two types viz. pulmonary embolism (PE) and deep vein thrombosis (DVT). Due to increasing awareness about thrombosis, there is increased demand for heparin. It is one of the major factors boosting the segment growth.

Route of Administration Outlook

Based on Route of Administration, the market is segmented into Subcutaneous and Intravenous. The subcutaneous segment dominated the market in 2020. It is expected to showcase the fastest growth rate and expected to see a lucrative CAGR over the forecast period due to less cost associated with hospitalization. Moreover, according to the patient’s perspective, the subcutaneous route is highly popular among the patients due to its ease of administration and increasing preference for home care, thus reducing the duration of treatment. Furthermore, other benefits of this route of administration comprise a lesser risk of systemic infection and better quality of life.

End Use Outlook

Based on End Use, the market is segmented into Outpatient and Inpatient. The outpatient segment garnered the maximum revenue share of the market in 2020 and expected to maintain its position over the forecast period. The preference for the subcutaneous route of administration has been increased among the patients. Thus, it is acting as a major factor contributing to the growth of the market.

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America dominated the heparin market in 2020. This is due to the rising cases of cardiovascular disorders in this region. Additionally, there is a higher level of healthcare expenditure, and increasing awareness among people which is expected to boost the regional market. Another factor that is likely to drive the demand for heparin is the advanced healthcare infrastructure in this region.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Baxter International, Inc., B. Braun Melsungen AG, Fresenius SE & Co. KGaA, Pfizer, Inc., Sanofi S.A., Teva Pharmaceuticals Industries Ltd., Hebei Changshan Biochemical Pharmaceutical Co., Ltd., Dr. Reddy’s Laboratories Ltd., LEO Pharma A/S, and Viatris, Inc.

Strategies deployed in Heparin Market

Apr-2021: Fresenius Kabi unveiled two new presentations of Heparin Sodium in convenient, ready-to-administer Freeflex IV bags in the US. Heparin Sodium in Sodium Chloride injection is used as an anticoagulant to maintain catheter patency.

Nov-2020: Fresenius Kabi came into partnership with Premier Inc. The partnership was aimed to supply pre-filled, single-use IV bags of heparin sodium injection, USP to healthcare providers, helping to stabilize the long-term supply of a medication that is necessary when performing a number of hospital inpatient procedures.

Nov-2019: Fresenius Kabi introduced the preservative-free Heparin Sodium Injection in the US.

Apr-2019: B. Braun Medical teamed up with Schreiner MediPharm, a global provider of specialty pharmaceutical labeling solutions. B. Braun recently introduced prefilled syringe of Heparin Sodium Injection, USP using Schreiner MediPharm’s label- integrated Needle-Trap system to the U.S. market.

Apr-2017: Fresenius Kabi signed an agreement to acquire Akorn, a manufacturer and marketer of prescription and over-the-counter pharmaceutical products. The acquisition is expected to strengthen the capabilities of both the companies.

Scope of the Study

Market Segments covered in the Report:

By Type
  • Low Molecular Weight Heparin
  • Unfractionated Heparin
  • Ultra-low Molecular Weight Heparin
By Application
  • Atrial Fibrillation
  • Coronary Artery Disease
  • Venous Thromboembolism
  • Renal Impairment
  • Other Applications
By Route of Administration
  • Subcutaneous
  • Intravenous
By End Use
  • Outpatient
  • Inpatient
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
Companies Profiled
  • Baxter International, Inc.
  • B. Braun Melsungen AG
  • Fresenius SE & Co. KGaA
  • Pfizer, Inc.
  • Sanofi S.A.
  • Teva Pharmaceuticals Industries Ltd.
  • Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • LEO Pharma A/S
  • Viatris, Inc.
Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • B. Braun Melsungen AG
  • Fresenius SE & Co. KGaA
  • LEO Pharma A/S
  • Pfizer, Inc.
  • Sanofi S.A.
  • Viatris, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Heparin Market, by Type
1.4.2 Global Heparin Market, by Application
1.4.3 Global Heparin Market, by Route of Administration
1.4.4 Global Heparin Market, by End Use
1.4.5 Global Heparin Market, by Geography
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Global Heparin Market by Type
3.1 Global Low Molecular Weight Heparin Market by Region
3.2 Global Unfractionated Heparin Market by Region
3.3 Global Ultra-low Molecular Weight Heparin Market by Region

Chapter 4. Global Heparin Market by Application
4.1 Global Atrial Fibrillation Market by Region
4.2 Global Coronary Artery Disease Market by Region
4.3 Global Venous Thromboembolism Market by Region
4.4 Global Renal Impairment Market by Region
4.5 Global Other Applications Market by Region

Chapter 5. Global Heparin Market by Route of Administration
5.1 Global Subcutaneous Market by Region
5.2 Global Intravenous Market by Region

Chapter 6. Global Heparin Market by End Use
6.1 Global Outpatient Market by Region
6.2 Global Inpatient Market by Region

Chapter 7. Global Heparin Market by Region
7.1 North America Heparin Market
7.1.1 North America Heparin Market by Type
7.1.1.1 North America Low Molecular Weight Heparin Market by Country
7.1.1.2 North America Unfractionated Heparin Market by Country
7.1.1.3 North America Ultra-low Molecular Weight Heparin Market by Country

Chapter 8. North America Heparin Market by Application
8.1.1.1 North America Atrial Fibrillation Market by Country
8.1.1.2 North America Coronary Artery Disease Market by Country
8.1.1.3 North America Venous Thromboembolism Market by Country
8.1.1.4 North America Renal Impairment Market by Country
8.1.1.5 North America Other Applications Market by Country
8.1.2 North America Heparin Market by Route of Administration
8.1.2.1 North America Subcutaneous Market by Region
8.1.2.2 North America Intravenous Market by Region
8.1.3 North America Heparin Market by End Use
8.1.3.1 North America Outpatient Market by Country
8.1.3.2 North America Inpatient Market by Country
8.1.4 North America Heparin Market by Region
8.1.4.1 US Heparin Market
8.1.4.1.1 US Heparin Market by Type
8.1.4.1.2 US Heparin Market by Application
8.1.4.1.3 US Unfractionated Heparin Market by Route of Administration
8.1.4.1.4 US Heparin Market by End Use
8.1.4.2 Canada Heparin Market
8.1.4.2.1 Canada Heparin Market by Type
8.1.4.2.2 Canada Heparin Market by Application
8.1.4.2.3 Canada Heparin Market by Route of Administration
8.1.4.2.4 Canada Heparin Market by End Use
8.1.4.3 Mexico Heparin Market
8.1.4.3.1 Mexico Heparin Market by Type
8.1.4.3.2 Mexico Heparin Market by Application
8.1.4.3.3 Mexico Unfractionated Heparin Market by Application
8.1.4.3.4 Mexico Heparin Market by Application
8.1.4.4 Rest of North America Heparin Market
8.1.4.4.1 Rest of North America Heparin Market by Type
8.1.4.4.2 Rest of North America Heparin Market by Application
8.1.4.4.3 Rest of North America Heparin Market by Route of Administration
8.1.4.4.4 Rest of North America Heparin Market by Application
8.2 Europe Heparin Market
8.2.1 Europe Heparin Market by Type
8.2.1.1 Europe Low Molecular Weight Heparin Market by Country
8.2.1.2 Europe Unfractionated Heparin Market by Country
8.2.1.3 Europe Ultra-low Molecular Weight Heparin Market by Country
8.2.2 Europe Heparin Market by Application
8.2.2.1 Europe Atrial Fibrillation Market by Country
8.2.2.2 Europe Coronary Artery Disease Market by Country
8.2.2.3 Europe Venous Thromboembolism Market by Country
8.2.2.4 Europe Renal Impairment Market by Country
8.2.2.5 Europe Other Applications Market by Country
8.2.3 Europe Heparin Market by Route of Administration
8.2.3.1 Europe Subcutaneous Market by Region
8.2.3.2 Europe Intravenous Market by Region
8.2.4 Europe Heparin Market by End Use
8.2.4.1 Europe Outpatient Market by Country
8.2.4.2 Europe Inpatient Market by Country
8.2.5 Europe Heparin Market by Region
8.2.5.1 Germany Heparin Market
8.2.5.1.1 Germany Heparin Market by Type
8.2.5.1.2 Germany Heparin Market by Application
8.2.5.1.3 Germany Heparin Market by Route of Administration
8.2.5.1.4 Germany Heparin Market by End Use
8.2.5.2 UK Heparin Market
8.2.5.2.1 UK Heparin Market by Type
8.2.5.2.2 UK Heparin Market by Application
8.2.5.2.3 UK Heparin Market by Route of Administration
8.2.5.2.4 UK Heparin Market by End Use
8.2.5.3 France Heparin Market
8.2.5.3.1 France Heparin Market by Type
8.2.5.3.2 France Heparin Market by Application
8.2.5.4 Russia Heparin Market
8.2.5.4.1 Russia Heparin Market by Type
8.2.5.4.2 Russia Heparin Market by Application
8.2.5.4.3 Russia Heparin Market by Route of Administration
8.2.5.4.4 Russia Heparin Market by End Use
8.2.5.5 Spain Heparin Market
8.2.5.5.1 Spain Heparin Market by Type
8.2.5.5.2 Spain Heparin Market by Application
8.2.5.5.3 Spain Heparin Market by Route of Administration
8.2.5.5.4 Spain Heparin Market by End Use
8.2.5.6 Italy Heparin Market
8.2.5.6.1 Italy Heparin Market by Type
8.2.5.6.2 Italy Heparin Market by Application
8.2.5.6.3 Italy Heparin Market by Route of Administration
8.2.5.7 Rest of Europe Heparin Market
8.2.5.7.1 Rest of Europe Heparin Market by Type
8.2.5.7.2 Rest of Europe Heparin Market by Application
8.2.5.7.3 Rest of Europe Heparin Market by Route of Administration
8.2.5.7.4 Rest of Europe Heparin Market by End Use
8.3 Asia Pacific Heparin Market
8.3.1 Asia Pacific Heparin Market by Type
8.3.1.1 Asia Pacific Low Molecular Weight Heparin Market by Country
8.3.1.2 Asia Pacific Unfractionated Heparin Market by Country
8.3.1.3 Asia Pacific Ultra-low Molecular Weight Heparin Market by Country
8.3.2 Asia Pacific Heparin Market by Application
8.3.2.1 Asia Pacific Atrial Fibrillation Market by Country
8.3.2.2 Asia Pacific Coronary Artery Disease Market by Country
8.3.2.3 Asia Pacific Venous Thromboembolism Market by Country
8.3.2.4 Asia Pacific Renal Impairment Market by Country
8.3.2.5 Asia Pacific Other Applications Market by Country
8.3.3 Asia Pacific Heparin Market by Route of Administration
8.3.3.1 Asia Pacific Subcutaneous Market by Region
8.3.3.2 Asia Pacific Intravenous Market by Region
8.3.4 Asia Pacific Heparin Market by End Use
8.3.4.1 Asia Pacific Outpatient Market by Country
8.3.4.2 Asia Pacific Inpatient Market by Country
8.3.5 Asia Pacific Heparin Market by Region
8.3.5.1 China Heparin Market
8.3.5.1.1 China Heparin Market by Type
8.3.5.1.2 China Heparin Market by Application
8.3.5.1.3 China Heparin Market by Route of Administration
8.3.5.1.4 China Heparin Market by End Use
8.3.5.2 Japan Heparin Market
8.3.5.2.1 Japan Heparin Market by Type
8.3.5.2.2 Japan Heparin Market by Application
8.3.5.2.3 Japan Heparin Market by Route of Administration
8.3.5.2.4 Japan Heparin Market by End Use
8.3.5.3 India Heparin Market
8.3.5.3.1 India Heparin Market by Type
8.3.5.3.2 India Heparin Market by Application
8.3.5.3.3 India Heparin Market by Route of Administration
8.3.5.3.4 India Heparin Market by End Use
8.3.5.4 South Korea Heparin Market
8.3.5.4.1 South Korea Heparin Market by Type
8.3.5.4.2 South Korea Heparin Market by Application
8.3.5.4.3 South Korea Heparin Market by Route of Administration
8.3.5.4.4 South Korea Heparin Market by End Use
8.3.5.5 Singapore Heparin Market
8.3.5.5.1 Singapore Heparin Market by Type
8.3.5.5.2 Singapore Heparin Market by Application
8.3.5.5.3 Singapore Heparin Market by Route of Administration
8.3.5.5.4 Singapore Heparin Market by End Use
8.3.5.6 Malaysia Heparin Market
8.3.5.6.1 Malaysia Heparin Market by Type
8.3.5.6.2 Malaysia Heparin Market by Application
8.3.5.6.3 Malaysia Heparin Market by Route of Administration
8.3.5.6.4 Malaysia Heparin Market by End Use
8.3.5.7 Rest of Asia Pacific Heparin Market
8.3.5.7.1 Rest of Asia Pacific Heparin Market by Type
8.3.5.7.2 Rest of Asia Pacific Heparin Market by Application
8.3.5.7.3 Rest of Asia Pacific Heparin Market by Route of Administration
8.3.5.7.4 Rest of Asia Heparin Market by End Use
8.4 LAMEA Heparin Market
8.4.1 LAMEA Heparin Market by Type
8.4.1.1 LAMEA Low Molecular Weight Heparin Market by Country
8.4.1.2 LAMEA Unfractionated Heparin Market by Country
8.4.1.3 LAMEA Ultra-low Molecular Weight Heparin Market by Country
8.4.2 LAMEA Heparin Market by Application
8.4.2.1 LAMEA Atrial Fibrillation Market by Country
8.4.2.2 LAMEA Coronary Artery Disease Market by Country
8.4.2.3 LAMEA Venous Thromboembolism Market by Country
8.4.2.4 LAMEA Renal Impairment Market by Country
8.4.2.5 LAMEA Other Applications Market by Country
8.4.3 LAMEA Heparin Market by Route of Administration
8.4.3.1 LAMEA Subcutaneous Market by Region
8.4.3.2 LAMEA Intravenous Market by Region
8.4.4 LAMEA Heparin Market by End Use
8.4.4.1 LAMEA Outpatient Market by Country
8.4.4.2 LAMEA Inpatient Market by Country
8.4.5 LAMEA Heparin Market by Region
8.4.5.1 Brazil Heparin Market
8.4.5.1.1 Brazil Heparin Market by Type
8.4.5.1.2 Brazil Heparin Market by Application
8.4.5.1.3 Brazil Heparin Market by Route of Administration
8.4.5.1.4 Brazil Heparin Market by End Use
8.4.5.2 Argentina Heparin Market
8.4.5.2.1 Argentina Heparin Market by Type
8.4.5.2.2 Argentina Heparin Market by Application
8.4.5.3 Argentina Heparin Market by Route of Administration
8.4.5.3.1 Argentina Heparin Market by End Use
8.4.5.4 UAE Heparin Market
8.4.5.4.1 UAE Heparin Market by Type
8.4.5.4.2 UAE Heparin Market by Application
8.4.5.4.3 UAE Unfractionated Heparin Market by Route of Administration
8.4.5.4.4 UAE Heparin Market by End Use
8.4.5.5 Saudi Arabia Heparin Market
8.4.5.5.1 Saudi Arabia Heparin Market by Type
8.4.5.5.2 Saudi Arabia Heparin Market by Application
8.4.5.5.3 Saudi Arabia Heparin Market by Route of Administration
8.4.5.5.4 Saudi Arabia Heparin Market by End Use
8.4.5.6 South Africa Heparin Market
8.4.5.6.1 South Africa Heparin Market by Type
8.4.5.6.2 South Africa Heparin Market by Application
8.4.5.6.3 South Africa Heparin Market by Route of Administration
8.4.5.6.4 South Africa Heparin Market by End Use
8.4.5.7 Nigeria Heparin Market
8.4.5.7.1 Nigeria Heparin Market by Type
8.4.5.7.2 Nigeria Heparin Market by Application
8.4.5.7.3 Nigeria Heparin Market by Route of Administration
8.4.5.7.4 Nigeria Heparin Market by End Use
8.4.5.8 Rest of LAMEA Heparin Market
8.4.5.8.1 Rest of LAMEA Heparin Market by Type
8.4.5.8.2 Rest of LAMEA Heparin Market by Application
8.4.5.9 Rest of LAMEA Heparin Market by Route of Administration
8.4.5.9.1 Rest of LAMEA Heparin Market by End Use

Chapter 9. Company Profiles
9.1 Baxter International, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research & Development Expense
9.2 B. Braun Melsungen AG
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.3 Fresenius SE & Co. KGaA
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expenses
9.3.1 Recent strategies and developments:
9.3.1.1 Partnerships, Collaborations, and Agreements:
9.3.1.2 Acquisition and Mergers:
9.3.1.3 Product Launches and Product Expansions:
9.4 Pfizer, Inc.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Regional Analysis
9.4.4 Research & Development Expense
9.5 Sanofi S.A.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.6 Teva Pharmaceutical Industries Ltd.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expenses
9.7 Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
9.7.1 Company Overview
9.8 Dr. Reddy’s Laboratories Ltd.
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.9 LEO Pharma A/S
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Regional Analysis
9.9.4 Research & Development Expense
9.10. Viatris, Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expense
Note: Product cover images may vary from those shown
  • Baxter International, Inc.
  • B. Braun Melsungen AG
  • Fresenius SE & Co. KGaA
  • Pfizer, Inc.
  • Sanofi S.A.
  • Teva Pharmaceuticals Industries Ltd.
  • Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • LEO Pharma A/S
  • Viatris, Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll